TCT 2019: IDEAL LM Inconclusive, While Onyx ONE Boosts Polymer-Based DES
Executive Summary
Data from two late-breaking drug-eluting stent trials, presented on 26 September at Transcatheter Cardiovascular Therapeutics meeting in San Francisco, prompted mixed reactions from interventional cardiologists.
You may also be interested in...
ACC 2020: Medtronic’s Resolute Onyx DES Meets Goals In US/Japan High Bleeding Risk Patients
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.
TCT 2019: Evolve Short DAPT And Model U-SUS Study Show Short DAPT Was Comparable To Longer-Term DAPT
Data from two studies that looked at the safety of three-months dual antiplatelet therapy versus longer-term DAPT therapy, presented on 26 September at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, showed non-inferiority for short-term DAPT.
TCT 2019: A Preview Of Late-Breaking Trials; Analyst Expectations
Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.